The glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis
Molecular Psychiatry · 2024-07 · 29 (7) · 2261-2273
DOI: 10.1038/s41380-024-02473-0 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Molecular Psychiatry, online erschienen am 16.02.2024. Verfasst von Carolina Soares und 13 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Alzheimer Disease, Glutamic Acid, Brain. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technologic…, Alzheimer's Association, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education).
Themen: Demenz
Abstract (Originalsprache)
Glutamatergic neurotransmission system dysregulation may play an important role in the pathophysiology of Alzheimer's disease (AD). However, reported results on glutamatergic components across brain regions are contradictory. Here, we conducted a systematic review with meta-analysis to examine whether there are consistent glutamatergic abnormalities in the human AD brain. We searched PubMed and Web of Science (database origin-October 2023) reports evaluating glutamate, glutamine, glutaminase, glutamine synthetase, glutamate reuptake, aspartate, excitatory amino acid transporters, vesicular glutamate transporters, glycine, D-serine, metabotropic and ionotropic glutamate receptors in the AD human brain (PROSPERO #CDRD42022299518). The studies were synthesized by outcome and brain region. We included cortical regions, the whole brain (cortical and subcortical regions combined), the entorhinal cortex and the hippocampus. Pooled effect sizes were determined with standardized mean differences (SMD), random effects adjusted by false discovery rate, and heterogeneity was examined by I2 statistics. The search retrieved 6 936 articles, 63 meeting the inclusion criteria (N = 709CN/786AD; mean age 75/79). We showed that the brain of AD individuals presents decreased glutamate (SMD = -0.82; I2 = 74.54%; P < 0.001) and aspartate levels (SMD = -0.64; I2 = 89.71%; P = 0.006), and reuptake (SMD = -0.75; I2 = 83.04%; P < 0.001. We also found reduced α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPAR)-GluA2/3 levels (SMD = -0.63; I2 = 95.55%; P = 0.046), hypofunctional N-methyl-D-aspartate receptor (NMDAR) (SMD = -0.60; I2 = 91.47%; P < 0.001) and selective reduction of NMDAR-GluN2B subunit levels (SMD = -1.07; I2 = 41.81%; P < 0.001). Regional differences include lower glutamate levels in cortical areas and aspartate levels in cortical areas and in the hippocampus, reduced glutamate reuptake, reduced AMPAR-GluA2/3 in the entorhinal cortex, hypofunction of NMDAR in cortical areas, and a decrease in NMDAR-GluN2B subunit levels in the entorhinal cortex and hippocampus. Other parameters studied were not altered. Our findings show depletion of the glutamatergic system and emphasize the importance of understanding glutamate-mediated neurotoxicity in AD. This study has implications for the development of therapies and biomarkers in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
- Graduate Program in Biological Sciences: Pharmacology and Therapeutics, UFRGS, Porto Alegre, Brazil.
- Department of Biochemistry, UFRGS, Porto Alegre, Brazil.
- Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McGill University, Montreal, QC, Canada.
- Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux de l'Ouest-de-l'Île-de-Montréal, McGill University, Montreal, QC, Canada.
ORCID-Profile: Carolina Soares, Luiza Santos Machado, Andreia Rocha, Marco A De Bastiani, Tharick A Pascoal, Eduardo R Zimmer
Förderung
- Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technologic…
- Alzheimer's Association
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education)
- Fulbright Association
- Fonds de Recherche du Québec - Santé (Fonds de la recherche en sante du Quebec)
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (Research Support Foundation of the State of Rio Grande do Sul)
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)
- Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)
Zitieren
APA
Soares, C., Da Ros, L. U., Machado, L. S., Rocha, A., Lazzarotto, G., Carello-Collar, G., De Bastiani, M. A., Ferrari-Souza, J. P., Lussier, F. Z., Souza, D. O., Rosa-Neto, P., Pascoal, T. A., Bellaver, B., & Zimmer, E. R. (2024). The glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis. Molecular Psychiatry, 29(7), 2261-2273. https://doi.org/10.1038/s41380-024-02473-0
Vancouver
Soares C, Da Ros LU, Machado LS, Rocha A, Lazzarotto G, Carello-Collar G, et al. The glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis. Molecular Psychiatry. 2024;29(7):2261-2273. doi:10.1038/s41380-024-02473-0
BibTeX
@article{Soares2024,
author = {Soares, Carolina and Da Ros, Lucas Uglione and Machado, Luiza Santos and Rocha, Andreia and Lazzarotto, Gabriela and Carello-Collar, Giovanna and De Bastiani, Marco A and Ferrari-Souza, João Pedro and Lussier, Firoza Z and Souza, Diogo O and Rosa-Neto, Pedro and Pascoal, Tharick A and Bellaver, Bruna and Zimmer, Eduardo R},
title = {The glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis},
journal = {Molecular Psychiatry},
year = {2024},
volume = {29},
number = {7},
pages = {2261--2273},
doi = {10.1038/s41380-024-02473-0}
}
EUVIMED